Skip to main content

Geron Corporation (GERN)

NASDAQ: GERN · Delayed Price · USD
+0.14 (9.52%)
After-hours:Oct 25, 2021 7:59 PM EDT
0.02 (1.38%)
At close: Oct 25, 4:00 PM

Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.

It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation
Geron Logo
CountryUnited States
IPO DateJun 30, 1996
SectorHealth Care
CEOJohn Scarlett

Contact Details

919 East Hillsdale Boulevard
Foster City, California 94404
United States
Phone650 473 7700

Stock Details

Ticker SymbolGERN
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000886744
CUSIP Number374163103
ISIN NumberUS3741631036
Employer ID75-2287752

Key Executives

Dr. John A. ScarlettChief Executive Officer, President and Chairman
Olivia Kyusuk BloomExecutive Vice President of Finance, Chief Financial Officer and Treasurer
Dr. Andrew J. GrethleinExecutive Vice President and Chief Operating Officer
Melissa A. Kelly BehrsExecutive Vice President and Chief Business Officer
Dr. Aleksandra Rizo M.D., Ph.D.Executive Vice President and Chief Medical Officer
Suzanne MessereHead of Investor Relations and Corporate Communications
Stephen N. RosenfieldExecutive Vice President, Chief Legal Officer and Corporate Secretary
Shannon OdamVice President of Human Resources
Anil KapurChief Commercial Officer and Executive Vice President of Corporate Strategy